Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers
Alphamab Oncology believes it has what it takes to stand out from the deluge of checkpoint inhibitors currently in development — not just in China but globally. A syndicate of well-heeled investors now shares that confidence, infusing more than $100 million to fuel an ambitious drive through the clinic.
Advantech, PAG and China Venture Capital Fund led the Series A, which is expected to support Alphamab’s lead asset, KN035, all the way up to registrational trials and fund late-stage programs for three other clinical drug candidates. OrbiMed, Heritage Provider Network and Janchor Partners also chipped in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.